Imunon, Inc. (IMNN)
| Market Cap | 12.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.45M |
| Shares Out | 14.50M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,013,599 |
| Open | 0.892 |
| Previous Close | 0.854 |
| Day's Range | 0.809 - 0.892 |
| 52-Week Range | 0.480 - 3.650 |
| Beta | 2.09 |
| Analysts | Strong Buy |
| Price Target | 20.50 (+2,369.88%) |
| Earnings Date | Nov 7, 2024 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-vira... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IMNN stock is "Strong Buy." The 12-month stock price forecast is $20.5, which is an increase of 2,369.88% from the latest price.
News
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur...
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian canc...
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript
Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Kim Golodetz - Alliance Advisors IR Stacy Lindborg - President & Chief Executive Officer ...
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc...
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is...
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announ...
UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline
IMUNON to Host R&D Day on September 18th
R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, ...
Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript
Imunon, Inc. (NASDAQ:IMNN) Q2 2024 Results Conference Call August 14, 2024 11:00 AM ET Company Participants Kim Golodetz - IR Michael Tardugno - Executive Chairman Stacy Lindborg - President and CEO ...
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc...
Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients
IMUNON Inc IMNN stock is surging on Tuesday, with a strong session volume of 117.8 million as per data from Benzinga Pro.
Imunon's stock rockets after ovarian cancer treatment's positive trial results
Shares of Imunon Inc. skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
Phase 2 OVATION 2 Study of IMNN-001 a dministered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient...
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m.
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NAS...
First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focuse...
Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-genera...
Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript
Imunon, Inc. (NASDAQ:IMNN) Q1 2024 Earnings Conference Call May 13, 2024 11:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Michael Tardugno - Executive Chairman Stacy Lindborg -...
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, ...